Literature DB >> 28267621

Targeting hepatic macrophages to treat liver diseases.

Frank Tacke1.   

Abstract

Our view on liver macrophages in the context of health and disease has been reformed by the recognition of a remarkable heterogeneity of phagocytes in the liver. Liver macrophages consist of ontogenically distinct populations termed Kupffer cells and monocyte-derived macrophages. Kupffer cells are self-renewing, resident and principally non-migratory phagocytes, serving as sentinels for liver homeostasis. Liver injury triggers Kupffer cell activation, leading to inflammatory cytokine and chemokine release. This fosters the infiltration of monocytes into the liver, which give rise to large numbers of inflammatory monocyte-derived macrophages. Liver macrophages are very plastic and adapt their phenotype according to signals derived from the hepatic microenvironment (e.g. danger signals, fatty acids, phagocytosis of cellular debris), which explains their manifold and even opposing functions during disease. These central functions include the perpetuation of inflammation and hepatocyte injury, activation of hepatic stellate cells with subsequent fibrogenesis, and support of tumor development by angiogenesis and T cell suppression. If liver injury ceases, specific molecular signals trigger hepatic macrophages to switch their phenotype towards reparative phagocytes that promote tissue repair and regression of fibrosis. Novel strategies to treat liver disease aim at targeting macrophages. These interventions modulate Kupffer cell activation (e.g. via gut-liver axis or inflammasome formation), monocyte recruitment (e.g. via inhibiting chemokine pathways like CCR2 or CCL2) or macrophage polarization and differentiation (e.g. by nanoparticles). Evidence from mouse models and early clinical studies in patients with non-alcoholic steatohepatitis and fibrosis support the notion that pathogenic macrophage subsets can be successfully translated into novel treatment options for patients with liver disease. LAY
SUMMARY: Macrophages (Greek for "big eaters") are a frequent non-parenchymal cell type of the liver that ensures homeostasis, antimicrobial defense and proper metabolism. However, liver macrophages consist of different subtypes regarding their ontogeny (developmental origin), differentiation and function. Understanding this heterogeneity and the critical regulation of inflammation, fibrosis and cancer by macrophage subsets opens promising new options for treating liver diseases.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemokine; Cholestasis; HBV; HCC; HCV; Kupffer cell; Liver fibrosis; Macrophage; Monocyte; NASH

Mesh:

Year:  2017        PMID: 28267621     DOI: 10.1016/j.jhep.2017.02.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  238 in total

Review 1.  Molecular Pathways: Targeting the Microenvironment of Liver Metastases.

Authors:  Simon Milette; Jason K Sicklick; Andrew M Lowy; Pnina Brodt
Journal:  Clin Cancer Res       Date:  2017-06-14       Impact factor: 12.531

2.  Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.

Authors:  Sofia de Oliveira; Ruth A Houseright; Alyssa L Graves; Netta Golenberg; Benjamin G Korte; Veronika Miskolci; Anna Huttenlocher
Journal:  J Hepatol       Date:  2018-12-18       Impact factor: 25.083

3.  Graphene-Dendrimer Nanostars for Targeted Macrophage Overexpression of Metalloproteinase 9 and Hepatic Fibrosis Precision Therapy.

Authors:  Pedro Melgar-Lesmes; Aureli Luquero; Marina Parra-Robert; Adriana Mora; Jordi Ribera; Elazer R Edelman; Wladimiro Jiménez
Journal:  Nano Lett       Date:  2018-08-16       Impact factor: 11.189

4.  Inflammation and Ectopic Fat Deposition in the Aging Murine Liver Is Influenced by CCR2.

Authors:  Elizabeth C Stahl; Evan R Delgado; Frances Alencastro; Samuel T LoPresti; Patrick D Wilkinson; Nairita Roy; Martin J Haschak; Clint D Skillen; Satdarshan P Monga; Andrew W Duncan; Bryan N Brown
Journal:  Am J Pathol       Date:  2019-12-13       Impact factor: 4.307

Review 5.  Linking Race, Cancer Outcomes, and Tissue Repair.

Authors:  Jung S Byun; Samson Park; Ambar Caban; Alana Jones; Kevin Gardner
Journal:  Am J Pathol       Date:  2017-11-11       Impact factor: 4.307

Review 6.  CT and MR perfusion techniques to assess diffuse liver disease.

Authors:  Maxime Ronot; Benjamin Leporq; Bernard E Van Beers; Valérie Vilgrain
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 7.  Mechanisms of liver fibrosis and its role in liver cancer.

Authors:  Debanjan Dhar; Jacopo Baglieri; Tatiana Kisseleva; David A Brenner
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-10

8.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4-/- Mouse.

Authors:  Anuradha Krishnan; Tomohiro Katsumi; Maria E Guicciardi; Adiba I Azad; Nazli B Ozturk; Christy E Trussoni; Gregory J Gores
Journal:  Am J Pathol       Date:  2020-03-30       Impact factor: 4.307

9.  Liver Tumor Microenvironment.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Moris; Timothy M Pawlik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 10.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.